HealthTree is currently interviewing patients who have received the bispecific antibody talquetamab (TALVEY). This bispecific antibody that targets GPRC5D. It works by attracting the innate immune system to come and kill the myeloma cells. If you have received talquetamab (TALVEY) and are interested in participating, please react to this post so we can provide more details about the study by mail. If you haven't received TALVEY but know someone who has, please share this post with them.